Evidence map›Paper›PMID 39846759›Full record

ArticleMicrobiology spectrum2025

Antifungal susceptibility testing and determination of local epidemiological cut-off values for

Vasiliki Kroustali, Lamprini Kanioura, Esmeralda Resoulai, Maria Siopi, Stavroula Antonopoulou, Joseph Meletiadis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vasiliki KroustaliClinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0009-0007-7453-9489
Lamprini Kanioura"MycoLab", Diagnostic Laboratory of Sexually Transmitted Diseases, Specific Infectious Diseases, Fungal, Microbiological and Cytologic Examinations, Athens, Greece.
Esmeralda ResoulaiClinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Maria SiopiClinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-5924-1007
Stavroula Antonopoulou *Department of Clinical Microbiology, General Hospital "G. Gennimatas", Athens, Greece.
Joseph Meletiadis *Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-8869-1509

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The lack of clinical breakpoints and epidemiological cut-off values (ECOFFs) for antifungals prescribed for vulvovaginal candidiasis (VVC) make interpretation of antifungal susceptibility data difficult. This leads to empirical prescribing, poor clinical management and emergence of resistance. The

Indexed as

Antifungal AgentsCandidaCandidiasis, VulvovaginalAdultAzolesCandida albicansDrug Resistance, FungalFemaleFluconazoleHumansMicrobial Sensitivity TestsPichiaAntifungal AgentsAzolesFluconazoleantifungal susceptibility testinglocal epidemiological cut-off valuesresistancevulvovaginal candidiasis

Identifiers

PMID39846759
PMCPMC11878056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.